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Abstract
Background: Radiological monitoring of malignant pleural mesothelioma (MPM) using modified RECIST criteria is
limited by low sensitivity and inter-observer variability. Serial serum mesothelin measurement has shown utility in
the assessment of treatment response during chemotherapy but has never been assessed in the longer term follow
up of patients.
Methods: This is a single centre study of consecutive patients diagnosed with MPM who received chemotherapy
or best supportive care (BSC). Serum mesothelin measurements with paired 6 monthly CT scans were performed
following the completion of chemotherapy, or from baseline in the BSC group. Changes in mesothelin were
correlated with radiological progression and overall survival.
Results: Forty-one patients with MPM were recruited and followed up for a minimum of 12 months (range
12–21 months). The majority of patients (n = 23) received chemotherapy with pemetrexed and cisplatin.
Across the cohort a 10% rise in serum mesothelin could predict radiological progression with a sensitivity of
96% (IQR; 79–100) and specificity of 74% (IQR; 50–91). Sensitivity fell to 80% in sarcomatoid only disease.
Patients with a rising mesothelin at 6 months had significantly worse overall survival (175 days) compared to
stable/falling levels (448 days) (p = 0.003).
Conclusions: This is the first study to assess serum mesothelin’s ability to detect progression of MPM following
chemotherapy or during BSC. A 10% rise in serum mesothelin level showed excellent sensitivity at predicting
progressive disease. Mesothelin measurement has several advantages over serial CT imaging including
reducing hospital visits and cost.
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Background
Malignant pleural mesothelioma (MPM) is an aggressive
malignancy with a median survival of 9–14 months [1].
There has been little improvement in overall survival
from the disease over the last decade with limited devel-
opment of effective treatments. Chemotherapy is the
only treatment modality that has shown to improve sur-
vival following the results of a large randomised control
trial (RCT) of pemetrexed and cisplatin which conferred
an additional 2 months to overall survival compared to
cisplatin alone [2]. Due to a response rate of only 25%
and a significant side effect profile many patients decline
or are unsuitable for first line chemotherapy [3]. The
role of non-chemotherapeutic options such as biological
treatments or immunotherapy is the topic of many
ongoing clinical trials [4–8]. Additionally, the efficacy of
second line chemotherapy in patients who have pro-
gressed following standard chemotherapy is uncertain
with promising reports from the use of vinorelbine,
gemcitabine or re-challenging with pemetrexed [9–12].
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Given the low response rate to conventional treatment,
and uncertainty around the efficacy of newer therapies,
the ability to accurately monitor disease is essential for
oncologists and trialists. The current standard for moni-
toring is, as for many tumours, serial computed tomog-
raphy (CT) scans. However, unlike many tumours, MPM
does not grow spherically, instead growing as a ‘rind’
encasing the thoracic cavity. An adaptation of the Re-
sponse Evaluation Criteria in Solid Tumours (RECIST)
to the modified RECIST criteria has only partially
allowed for this unique morphology. Other issues in-
cluding low sensitivity to predict progression, subjectiv-
ity in radiologists’ choice of measurement sites and
complications from the presence of pleural plaques or
fluid, mean research into a more robust and reprodu-
cible radiological marker is ongoing [13]. Studies have
shown that serial FDG-PET (Fludeoxyglucose positron
emission tomography) scanning can be used to predict
response [14] but is significantly limited by false positive
uptake in inflamed tissue from surgical intervention or
pleurodesis, as well as restricted availability or limited
reimbursement from insurers [15].
Serum or pleural fluid biomarkers that could reflect
disease activity are an attractive option for MPM given
the difficulties with radiological assessment. The most
investigated is mesothelin, a membrane-bound glycopro-
tein overexpressed by malignant mesothelial cells [16].
Soluble mesothelin is found in the blood and pleural
fluid of patients with MPM and levels correlate with
tumour stage and bulk. It lacks the sensitivity to be used
as a diagnostic marker given reduced expression in non-
epithelioid MPM. There remains uncertainty as to
whether the baseline mesothelin level is a useful pre-
dictor of prognosis. However, a systematic review we
performed found 8 studies that had assessed serum
mesothelin’s ability to monitor disease during chemo-
therapy and found it correlated with radiological
markers and survival [17]. No studies had assessed the
utility of mesothelin in longer term monitoring patients
not currently receiving chemotherapy. In this prospect-
ive cohort study, we aim to assess the ability of serum
mesothelin to monitor disease at later timepoints in
patients who have completed chemotherapy or those
receiving best supportive care (BSC).
Methods
Patients
From February 2014 to October 2016 consecutive pa-
tients were prospectively recruited to a longitudinal
study of biomarkers alongside normal clinical care. All
patients gave written informed consent and the trial was
approved by the South West REC (Ref 08/H0102/11).
Eligibility criteria included; histocytologically confirmed
malignant pleural mesothelioma, age over 18 years and
an expected life expectancy of greater than 3 months. At
baseline, patient demographics, method of diagnosis of
MPM and WHO performance status were recorded.
Blood samples were taken at baseline and a full staging
CT scan was performed.
This study had no impact on the treatments received
by the patient, but treatment information was recorded.
For eligible patients, chemotherapy was given in the
form of up to 6 cycles of Pemetrexed and Cisplatin or
Carboplatin (as tolerated by the patient).
CT imaging
All patients had a baseline full staging CT scan. Patients
who received chemotherapy had a CT scan at 3, 6 and
12 months to assess recurrence. Patients in the non-
chemotherapy group had a CT scan at clinically appro-
priate intervals (usually every 6 months). CT scans were
reported by two methods. Firstly, they were all reported
in a standard reporting fashion for clinical purposes by a
consultant thoracic radiologist who classified the scans
into radiological progression, stability or partial response
but did not use a formal reporting criteria (herein de-
scribed as the ‘clinically reported CT’). Secondly, another
independent radiologist assessed the imaging using the
modified RECIST criteria (herein described as the ‘mRE-
CIST CT’). The mRECIST criteria defines complete
response as the disappearance of all target lesions with
no visible tumour elsewhere and partial response (PR) as
at least a 30% reduction in cumulative tumour measure-
ment. Progressive disease (PD) is defined as an increase
of 20% in cumulative tumour measurement or emer-
gence of new lesions. Stable disease (SD) is defined as
not fulfilling the criteria for PR of PD. Both radiologists
were blinded to mesothelin results.
Mesothelin measurement
Serum samples for mesothelin testing were collected at
respiratory or oncology clinic appointments. They were
analysed routinely using the commercial Mesomark™
ELISA (Fujirebio) using manufacturer’s recommended
methods for sample processing, by investigators unware of
the patients clinical or radiological characteristics. Base-
line blood tests of liver and renal function were collected
but not performed again unless clinically indicated.
Statistical analysis
Mesothelin levels are not normally distributed so results
are presented as medians with interquartile ranges
(IQR). Analysis of baseline levels of mesothelin between
groups was performed using the Mann Whitney U test,
with a p value of less than 0.05 considered statistically
significant. Cox regression analysis was performed to
determine whether baseline mesothelin, as both a con-
tinuous and bivariate variable, impacted on survival.
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The ability of serum mesothelin to predict radiological
progression was assessed using timepoint analysis. A
mesothelin measurement with a paired CT scan (defined
as performed within a maximum of 31 days of each
other) was called a ‘timepoint’. These timepoints were
grouped depending on the time from baseline into 3
monthly intervals. Two timepoints in the same patient
allowed for a ‘comparison’ between the percentage
change in mesothelin level and the radiological report
(both clinically reported and mRECIST CTs). Patients
were grouped into whether their CT scan showed pro-
gression of disease or stable disease/partial response.
This study aimed to assess the role of mesothelin in
patients not currently undergoing treatment, so any
timepoints during or within 1 month of chemotherapy
were not included. Additionally, for any patients who
had previously received chemotherapy, the post-
chemotherapy mesothelin and CT scan was considered
the new point of reference, not the pre-chemotherapy
baseline.
For the timepoint analysis a change in mesothelin was
defined as a relative change from the previous mesothelin
level, either ‘falling’ or ‘rising’, with separate analyses per-
formed using 10%, 15% and 25% cut-offs. The thresholds
were calculated by the following method; ((Later time-
point mesothelin – Earlier timepoint mesothelin)/Earlier
timepoint mesothelin) * 100. The ability of mesothelin to
predict radiological progression was assessed using sensi-
tivity, specificity, predictive values and accuracy. Explora-
tory subgroup analysis was carried out based on baseline
mesothelin level and histological type.
To further assess the ability of changes in mesothelin to
track disease, independent of radiological assessments, the
impact of a rising level on survival was calculated and
compared to stable mesothelin levels and other poor prog-
nostic indicators.
Results
Participants
In total, 41 patients with malignant pleural mesotheli-
oma were recruited to this study and had a mesothelin
taken at baseline alongside usual care (see Table 1). The
majority were males (35 vs 6) and the cohort had a
median age of 72 (range 58–83). Twenty-three patients
received chemotherapy in the form of Pemetrexed and
Cisplatin, with no patients being referred for surgical
intervention. Eighteen patients received no chemother-
apy either due to choice, poor performance status, or
intention for delayed chemotherapy by the physician.
Patients in the non-chemotherapy group were older on
average (75 vs 69) but had a similar distribution of histo-
logical subtypes. Three patients in the cohort were diag-
nosed on the basis of pleural fluid cytology, therefore
histological subtype was unknown.
Baseline mesothelin
All 41 patients had a serum mesothelin performed at
baseline, with a median of 2.3 nmol/L (IQR 1.2–6.6)
across the entire cohort. Baseline mesothelin was signifi-
cantly higher in the epithelioid (3.1 nmol/L IQR 1.25–
13.6) compared to non-epithelioid (1.3 nmol/L IQR
0.75–2.95) histological subtypes (p = 0.041). Survival of
the entire cohort was 15 months (IQR 10–23). When ana-
lysed as a bivariate variable (dichotomizing the cohort at a
mesothelin level of 2 nmol/) there was no difference
in survival between those with a low (< 2 nmol/L) or
high (> = 2 nmol/L) baseline mesothelin with median
survival times of 329 (IQR 225 to 587) and 452 days
(IQR 310 to 777) respectively (p = 0.191). Additionally,
baseline mesothelin did not impact on survival when ana-
lysed as a continuous variable (p = 0.193). There was no
significant difference on baseline mesothelin or change in
mesothelin levels depending on the patients’ baseline renal
function (eGFR).
Change in mesothelin and radiological progression
At baseline, from the cohort of 41 patients, all had a CT
scan within 31 days of a serum mesothelin measurement
for comparison to later timepoints. The numbers of
other timepoints were; 5 at 3 months, 21 at 6 months, 4
at 9 months, 15 at 12 months, and 6 at later timepoints.
This allowed for 43 comparisons, with 25 in the post-
chemo group and 18 in the non-chemotherapy group.
The median time between mesothelin measurement and
CT was 13 days (range 0 to 31 days).
When all comparisons were amalgamated across the
cohort there was no change in median mesothelin levels
in patients who had not progressed on the clinically re-
ported CT (0.0 nmol/l (IQR -0.6 – 0.4)). This compared
Table 1 Baseline demographics, mesothelins and survival
Post-chemotherapy Non-chemotherapy
Number 23 18
Median age (range) 69 (58–77) 75 (67–83)
Male/Female 22/1 13/5
Histology
Epithelioid 14 11
Biphasic 3 1
Sarcomatoid 5 4
Unknown 1 2
Baseline mesothelin
Median 1.9 3.4
(IQR) (1.2–13.4) (1.2–6.4)
Survival (months)
Median 17 10
(IQR) (14–26) (7–22)
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to a rise of 1.8 nmol/l (IQR 0.7–1.8) in patients with
radiological progression of disease (p < 0.001).
Results from Table 2 demonstrated the ability of a
rising mesothelin to predict radiological progression on
both clinically reported and mRECIST CT in individual
patients. A variety of pre-defined cut-offs were tested.
Regardless of cut-off used, mesothelin tracked the clinic-
ally reported CT results with greater accuracy than
mRECIST CT reports. Resultantly, the clinically reported
CT has been used for the ongoing analysis. Figure 1 is a
waterfall plot of the absolute changes of mesothelin
divided by clinically reported CT report (SD and PR
versus PD). It demonstrated that the vast majority of
patients with radiologically progressive disease had a
rising mesothelin (with only 1 patient having a small fall
in level).
Further subgroup analysis was performed depending on
baseline mesothelin or histological subtype, see Table 3.
Serial changes in mesothelin predicted radiological pro-
gression with 100% sensitivity in patients with a high base-
line mesothelin (defined as > 2 nmol/l). There was a fall in
sensitivity and specificity in patients with low baseline
mesothelin or sarcomatoid disease, although sensitivity
remained above 90% in the former group.
Change in mesothelin and overall survival
At 6 months, patients with a rising mesothelin (using a
10% cut-off ) had a significantly shorter survival (from
the date of sampling) compared to those with a falling
or stable level (p = 0.003). Those with a rising mesothe-
lin had median survival of 175 days (IQR 80–211) com-
pared to 448 days (IQR 321 to 554). Patients with
radiologically progressive disease on clinically reported
CT had a median survival of 170 days (IQR 72–223)
from the date of CT scan compared to 433 days (IQR
255–581) in those with stable disease or partial response
(p = 0.001). The majority of CT scans (10/21) performed
at a 6 month time point were non-measurable using
mRECIST criteria so these results were not analyzable.
In a multivariate analysis including age (≥70 vs < 70),
histological subtype (epithelioid vs non-epithelioid) and
treatment modality neither change in mesothelin or
clinically reported CT remained significant.
Discussion
This study assessed the ability of serum mesothelin to de-
tect progression of MPM in patients following chemother-
apy or receiving best supportive care. To our knowledge
this is the first study to focus on longer term monitoring as
opposed to mesothelin’s role as a marker of treatment re-
sponse during or immediately after chemotherapy. The
ability to monitor MPM in these patients is becoming in-
creasingly important. However, no specific evidence exists
for how patients with MPM should be monitored following
first line chemotherapy. Recent guidelines have suggested
that 3–4 month follow up is good practice without specify-
ing what form this follow up should take https://www.brit-
thoracic.org.uk/standards-of-care/guidelines/bts-statement-
on-malignant-mesothelioma/. There is considerable vari-
ation in practice nationally, for two main reasons. Firstly,
until recently many oncologists felt there was no data to
support the role of second line chemotherapy in this set-
ting. In addition, there was limited access to clinical trials
after first line treatment. There was, therefore, no perceived
benefit from monitoring patients post first line chemother-
apy or in those having BSC. However, given promising re-
sults from second line chemotherapy trials, as well as non-
chemotherapeutic options this perception is changing. Sec-
ondly, no radiological marker has shown the ability to ac-
curately monitor disease. A serum biomarker that could
identify disease progression would be very useful to oncolo-
gists and physicians, with the additional benefit of reducing
patient burden and healthcare costs. Mesothelin is the most
studied serum biomarker for mesothelioma with the major-
ity of literature assessing its diagnostic potential. Although
a raised level is fairly specific for MPM, many patients with
non-epithelioid disease will have unrecordable levels even
at an advanced stage. This has limited its utility as a diag-
nostic test, although recent studies have attempted to com-
bine it with more novel markers [18, 19]. The role of
biomarkers in other malignancies has often begun as a pu-
tative diagnostic marker before becoming a marker of treat-
ment response or recurrence (CA125, PSA).
Table 2 Ability of mesothelin to predict radiological progression depending on cut-off used and radiological reporting method
Mesothelin Cut-off 10% 15% 25%
CT reporting method Clinically reported CT MRECIST Clinically reported CT MRECIST Clinically reported CT MRECIST
No. 43 25 43 25 43 25
Sensitivity 95.8 (78.8–99.8) 90.9 (58.7–99.7) 83.3 (62.6–95.3) 72.7 (39.0–93.9) 80.0 (59.3–93.2) 72.7 (39.0–93.9)
Specificity 73.7 (48.8–90.8) 57.1 (28.9–82.3) 84.2 (60.4–96.6) 71.4 (41.9–91.6) 84.2 (60.4–96.6) 71.4 (41.9–91.6)
PPV 82.1 (68.3–90.8) 62.5 (46.9–75.8) 87.0 (69.9–95.0) 66.7 (44.7–83.2) 87.0 (69.9–95.0) 66.7 (44.7–83.2)
NPV 93.3 (66.8–99.0) 88.9 (53.9–98.2) 80 (61.7–90.9) 76.9 (54.6–90.2) 76.2 (58.8–87.8) 76.9 (54.6–90.2)
Accuracy 86.0% 83.7% 0.81%
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Previous literature has shown that mesothelin can be
used as a marker of treatment response when measured
serially. The first example from Grigoriu and colleagues
[20] took patients with a positive (> 1 nM/L) mesothelin
at baseline receiving chemotherapy and immunotherapy
(n = 40). They found that in patients with a 10% or
greater rise in mesothelin there was a 75% chance of
radiological progression using mRECIST as well signifi-
cantly worse overall survival. The largest study of its
type [21] correlated both CT scans (mRECIST) and PET
(TGV and tumour volume) with change in mesothelin
levels after treatment (using a 25% cut-off ). In the
chemotherapy group (n = 55) the change in mesothelin
significantly correlated with radiological response on CT
(p = 0.023). Although only a minority of the cohort
(n = 28) could be reassessed using PET imaging, due to
prior pleurodesis or surgery, the change in both metabolic
activity (TGV) and tumour bulk strongly correlated with
change in mesothelin levels (p < 0.001). Survival analysis
demonstrated that the trend of mesothelin correlated with
survival in a multivariate model that included age, sex,
histology and treatment. Interestingly, this was not true
when tumour volume on PET was added to the model, in-
dicating that mesothelin was probably acting as a proxy
for tumour bulk.
Across the literature we found several different thresh-
olds for defining a clinically significant change in mesothe-
lin level, including 10% [20], 15% [22] and 25% [21].
Wheatley-Price and colleagues [23] performed a post-hoc
analysis of mesothelin values from a cohort of 42 patients
using absolute (5 mmol) and relative (10%) changes and
their correlation with survival, finding that relative
changes were more accurate. This current study assessed
a variety of cut-offs, finding that a 10% cut-off reduced the
specificity of a rising mesothelin level but had a sensitivity
of 96%. Given our aim was to assess the ability of
mesothelin to detect disease progression we felt this
reduction in specificity was justified with a false positive
rate of 28% but a false negative rate of only 4%.
We demonstrated that disease progression could be
detected using mesothelin with an accuracy of 86% and
NPV of 94%. Unlike some previous literature [20, 23]
this analysis did not exclude patients from the analysis
with low baseline mesothelin or non-epithelioid disease.
There has been uncertainty about the utility of serially
measuring mesothelin in these patients. In this study, 44%
(8/19) of patients with a mesothelin of less than 2 mmol/L
at baseline had an increased level (range 2.1–20.4) at later
timepoints. Additionally, when the analysis was limited to
patients with a baseline mesothelin of < 2 mmol there was
Fig. 1 Waterfall plot to show change in mesothelin between Progressive disease and Stable/Partial disease
Table 3 Ability of mesothelin to predict progression- subgroup analysis
Baseline Mesothelin> = 2 Baseline Mesothelin< 2 Non-Epithelioid
n 19 24 9
Progression on CT (Y/N) 13/6 11/13 5/4
Sensitivity 100 (75.3–100) 90.9 (58.7–99.7) 80.0 (28.4–99.5)
Specificity 83.3 (35.9–99.6) 69.2 (38.5–90.9) 75.0 (19.4–99.4)
PPV 92.7 (68.4–98.7) 71.4 (51.9–85.2) 80.0 (40.9–95.9)
NPV 100 90.0 (57.3–98.4) 75.0 (32.2–94.9)
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only a limited reduction in sensitivity to predict progres-
sion. Given the small subgroup, no firm recommendations
can be made regarding the utility of retesting mesothelin
when the baseline is negative (< 2 nmol/l). This needs
further assessment in other prospective studies.
This study had several limitations that could impact
on the conclusions drawn. The cohort of patients was
small, which has an impact on the conclusions of the
multivariate analyses, but comparable to other studies of
its type. This was an observational study alongside normal
clinical practice and there were instances where a
mesothelin was collected but the patient did not receive a
scan within the pre-allocated 1 month period. Addition-
ally, given the aggressive nature of MPM very few compar-
isons of timepoints over 12 months were available, but
this is likely to be a pragmatic assessment of following up
these patients in clinical practice. As previously mentioned
other studies have monitored the change in mesothelin
levels in response to systemic therapy. As a result, these
studies had a proportion of patients where mesothelin
levels fell considerably, which was correlated with radio-
logical ‘partial response’. Given this study focused on pa-
tients not receiving treatment there were few instances of
a falling mesothelin. Worsening renal function has been
shown to falsely elevate mesothelin levels [24]. Although
there was no difference in mesothelin sensitivity between
patients with normal and abnormal renal function at base-
line, there was no ongoing assessment during follow up.
Finally, the difficulty with studies of this type is that the
current ‘gold standard’ of monitoring (mRECIST CT)
which mesothelin trends are compared to has been shown
to be insensitive at detecting early progression. This
analysis found that mesothelin correlated better with the
clinically reported CT scan compared to mRECIST report-
ing, a finding of other similar studies [23]. Additionally,
over half (25/43) of the CT scans used in the timepoint
analysis were non-measurable by mRECIST criteria with a
short axis diameter of less than 1 cm. This is another
shortcoming of the mRECIST criteria that limits its sensi-
tivity and applicability in clinical practice. It is for this rea-
son that we assessed the impact of a changing mesothelin
levels on survival as a means of validation, finding that a
rising mesothelin at 6 months was a poor prognostic indi-
cator. As with other cancer biomarkers [25] the reason for
several ‘false-positive’ results (where a rising mesothelin
occurred in the context of radiologically stable disease)
could be because changes in mesothelin preceded radio-
logical change.
Conclusions
We have demonstrated that a rising serum mesothelin is
a sensitive marker of progression in the follow up of pa-
tients with MPM. Given the emergence of effective non-
chemotherapeutic treatments and second-line agents,
accurate disease monitoring is becoming increasingly
important. This study has demonstrated that regular
mesothelins could be used as a cost effective adjunct or
alternative to serial CT scanning.
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